Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Edwards Lifesciences Corp EW

Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter... see more

NYSE:EW - Post Discussion

Edwards Lifesciences Corp > EW Price Target Alert: $90.00. Issued by Oppenheimer
View:
Post by whytestocks on Jul 25, 2024 5:46pm

EW Price Target Alert: $90.00. Issued by Oppenheimer

NEWS: $EW EW Price Target Alert: $90.00. Issued by Oppenheimer2024-07-25 16:00:05 ET Suraj Kalia from Oppenheimer issued a price target of $90.00 for EW on 2024-07-25 13:36:00. The adjusted price target was set to $90.00. At the time of the announcement, EW was trading at $60.58. The overall price target consensus is at $109.85 wit...EW - EW Price Target Alert: $90.00. Issued by Oppenheimer
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities